Bedside End-tidal Carbon Dioxide in Evaluation for Pulmonary Embolism BACKGROUND P ulmonary embolism (PE) is associated with approximately 100,000 deaths per year in the United States and the incidence of deep vein thrombosis/pulmonary embolism in the United States is estimated at more than 350,000 cases annually. 1 The diagnosis of pulmonary embolism poses a diagnostic challenge in the emergency department (ED), despite validated decision rules, laboratory tests, and radiographic imaging. 2, 3 While a simple laboratory test would be ideal for diagnosis, the well-known D-dimer test is, at its best, only about 54% specific. 4 The criterion standard pulmonary artery computed tomography angiography (CTA) has numerous downsides including a requirement of clinical stability for transport to radiology, administration of potentially nephrotoxic contrast agents, and radiation exposure to patients, some of whom may be pregnant. Hemodynamically significant PE increases pulmonary dead space and therefore increases the alveolar dead space fraction; however, calculating this involves invasive testing with ABG and a slightly cumbersome calculation. 5, 6 Studies suggest that it is possible to use ETCO 2 alone to screen for PE with the resultant increase in dead space causing the amount of exhaled ETCO 2 to be lower in patients with clinically significant PE as opposed to invasive ABG testing. 7, 8 However, these studies have typically included patients admitted to the hospital, which represent a fraction of those seen in the ED, and likely have a higher prevalence of PE. No study has prospectively evaluated real-time ETCO 2 in ED patients suspected of having PE. We sought to determine if ETCO 2 can rule out hemodynamically significant PE, hypothesizing that no patients with hemodynamically significant PE would have an ETCO 2 greater than 35 mm Hg. Our secondary hypothesis was that the mean ETCO 2 would be significantly lower in patients with PE versus those without PE. Full institutional review board (IRB) approval was obtained through MedStar Washington Hospital Center's IRB prior to initiation of this study.
METHODS
Prospective observational study of a convenience sample of adults presenting to a tertiary care, academic, urban ED, which receives 87,000 visits annually, between June 6, 2017, and July 28 2017, Monday through Friday from 8 AM until 10 PM. Study subjects were adults 18 or older in whom the clinical team suspected PE; had D-dimer, pulmonary CTA, or ventilation/perfusion nuclear (V/Q) scan ordered; and were deemed stable to consent. Patients who were pregnant, incarcerated, under arrest, unable to consent for themselves, or not fluent in English were excluded. Potential subjects were approached by one of two trained medical student research assistants who consented and enrolled patients prior to definitive testing.
Patients were placed on a standard model bedside nasal cannula (nasal CO 2 cannula by Spacelabs Medical Inc., 704-0014-00) using General Electric Dash 5000 monitors and their ETCO 2 was measured over three breaths by waveform capnography. The mean of the three measurements was calculated. All measurements, demographics, vital signs, and testing results were recorded using a standardized data collection sheet. After definitive testing, a physician chart reviewer extracted which patients had a PE and, of those, if they were clinically significant. A true positive was defined as CTA or V/Q consistent with PE. A true negative was defined as a negative D-dimer, negative CTPE or very low or low probability VQ scan that the clinical team did not treat. A PE was considered hemodynamically significant if it met a priori criteria based on previous studies. 9 This included troponin elevated from baseline, newly elevated BNP, echocardiogram with evidence of right ventricular dysfunction, tachycardia (heart rate > 100 beats/min), hypoxia (oxygen saturation < 93% on room air), intermediate care or intensive care unit level of admission, or hypotension systolic < 100 mm Hg, diastolic < 60 mm Hg).
Sample size calculations were performed for a beta of 0.20 and alpha error ratio of 0.05, based on our previously calculated PE incident rate of 6% and the previously described standard deviation among ETCO 2 measurement in ED patients of 2.8 mm Hg. Using this method, the ideal sample size was calculated to be 68 patients. Demographic differences between the groups were tested using two-sample t-tests and nonparametric Wilcoxon rank-sum test for continuous measurements. Categorical variables were tested using Fisher's exact test. Comparison between ETCO 2 in the two groups was made using robust regression models with iteratively reweighted least squares (IRLS) method, adjusting for COPD status, age, and sex. Presence of COPD was considered a possible confounder; a preplanned secondary analysis was performed excluding patients with COPD given the assumption that patients with COPD would have increased physiologic dead space and therefore deranged ETCO 2 . Therefore, we used robust regression models to estimate the mean ETCO 2 difference between PE and non-PE groups adjusting for COPD status, age, and sex of the patients. IRLS method was used to estimate the difference between ETCO 2 means. It has a tendency to underestimate the standard errors therefore bootstrapped quantile regression was recommended with data resampling and was used to compare medians. Statistical analyses were conducted in Stata 14 (www.stata.com, StataCorp LP).
RESULTS
A total of 69 patients with suspected PE were enrolled in the study. The median age of study subjects was 55 and 68% were female. Of the 69 subjects, nine (13%) had PE identified on CT or V/Q scanning; seven (10.1%) were hemodynamically significant. Patient characteristics did not vary significantly between patients with hemodynamically PE and those without with regards to sex, COPD, pulse oximetry, heart rate, or blood pressure. The primary hypothesis was rejected as two of the patients with significant PE had a mean ETCO 2 greater than 35 mm Hg (see Table 1 ). IRLS method showed that the mean (AESD) ETCO 2 level is significantly lower by 6.6 mm Hg for the PE group, 35.7 (AE5.6) versus 29.1 (AE7.7;, Hypoxia, elevated troponin and BNP BNP = brain natriuretic peptide; BP = blood pressure; ETCO 2 = end-tidal carbon dioxide; HR = heart rate (beats/min); NC = nasal cannula; RA = room air; PE = pulmonary embolism. p < 0.001). Bootstrapped quantile regression with 300 repetitions show that the median ETCO 2 was significantly lower by 7.0 units (35.7 mm Hg vs. 29.7 mm Hg, p = 0.04).
DISCUSSION
Emergency physicians are on the front line of diagnosis and treatment of PE and many considerations must be made in the workup of patients in whom this diagnosis is suspected. Previous studies have described significantly lower ETCO 2 in patients with massive PE and some have even generated receiver operator curves with specific cutoffs for ETCO 2 in patients with hemodynamically significant PE. 10 Our study found that two patients with significant PE had an ETCO 2 above these previously estimated cutoffs, refuting our primary hypothesis. In this way, we continue to call into question the utility of ETCO 2 alone as a screening modality for PE. However, our secondary hypothesis, despite our small sample size, proved correct in that there appears to be an overall meaningful difference in ETCO 2 in patients with hemodynamically significant PE versus those who do not. Previous studies have indicated a high degree of sensitivity when dead space is combined with D-dimer to diagnose PE; while further studies are warranted, our study suggests that ETCO 2 can aid in the diagnosis of PE. This will be most helpful in patients in whom bedside testing is more appropriate, for example, those with hemodynamic instability making CT scan unobtainable.
LIMITATIONS
This is a single-center study performed at an urban tertiary academic center using convenience sampling and accordingly has resultant limitations regarding its external validity. Enrollment hours and the notification process were designed to be as reflective as possible of the ED population given these restraints. The relative incidence of hemodynamically significant PE in our population was 10.1%. While this is consistent with previous studies of PE, the number of patients in this group was much lower than the number of patients without PE who were enrolled, necessitating use of nonparametric statistical analysis. Additionally, we required subjects to consent for themselves, potentially limiting the acuity of our cohort and possibly resulting in the exclusion of the more critically ill subjects likely to have increased dead space and therefore even lower ETCO 2 .
